Literature DB >> 22266551

Prognostic significance of adenocarcinoma histology in women with cervical cancer.

Vijaya Galic1, Thomas J Herzog, Sharyn N Lewin, Alfred I Neugut, William M Burke, Yu-Shiang Lu, Dawn L Hershman, Jason D Wright.   

Abstract

OBJECTIVES: We performed a population-based analysis to determine the effect of histology on survival for women with invasive cervical cancer.
METHODS: The Surveillance, Epidemiology and End Results database was used to identify women with stage IB-IVB cervical cancer treated from 1988 to 2005. Patients were stratified by histology (squamous, adenocarcinoma, and adenosquamous). Clinical characteristics, patterns of care, and outcomes were analyzed using multivariable logistic regression and Cox proportional hazards models.
RESULTS: A total of 24,562 patients were identified including 18,979 (77%) women with squamous cell carcinomas, 4103 (17%) with adencarcinomas, and 1480 (6%) with adenosquamous tumors. Women with adenocarcinomas were younger, more often white, and more frequently married than patients with squamous cell tumors (p<0.0001 for all). Patients with adenocarcinomas were more likely to present with early-stage disease (p<0.0001). At diagnosis, 26.7% of women with adenocarcinomas had stage IB1 tumors compared to 16.9% of those with squamous cell carcinomas. Among women with early-stage (IB1-IIA) tumors, patients with adenocarcinomas were 39% (HR=1.39; 95% CI, 1.23-1.56) more likely to die from their tumors than those with squamous cell carcinomas. For patients with advanced-stage disease (stage IIB-IVA) women with adenocarcinomas were 21% (HR=1.21; 95% CI, 1.10-1.32) more likely to die from their tumors than those with squamous neoplasms. Five-year survival for stage IIIB neoplasms five-year survival was 31.3% (95% CI, 29.2-33.3%) for squamous tumors vs. 20.3% (95% CI, 14.2-27.1%) for adenocarcinomas.
CONCLUSION: Cervical adenocarcinomas are more common in younger women and white patients. Adenocarcinoma histology negatively impacts survival for both early and advanced-stage carcinomas.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22266551     DOI: 10.1016/j.ygyno.2012.01.012

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  75 in total

1.  LTPB2 acts as a prognostic factor and promotes progression of cervical adenocarcinoma.

Authors:  Yuan Ren; Huan Lu; Danmei Zhao; Yangjun Ou; Kang Yu; Jiandong Gu; Li Wang; Shuheng Jiang; Mo Chen; Jinghao Wang; Rong Zhang; Congjian Xu
Journal:  Am J Transl Res       Date:  2015-06-15       Impact factor: 4.060

2.  Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation.

Authors:  Peter G Rose; James J Java; Charles W Whitney; Frederick B Stehman; Rachelle Lanciano; Gillian M Thomas
Journal:  Gynecol Oncol       Date:  2014-08-23       Impact factor: 5.482

3.  Comparison of outcomes for MR-guided versus CT-guided high-dose-rate interstitial brachytherapy in women with locally advanced carcinoma of the cervix.

Authors:  Sophia C Kamran; Matthias M Manuel; Linda P Cho; Antonio L Damato; Ehud J Schmidt; Clare Tempany; Robert A Cormack; Akila N Viswanathan
Journal:  Gynecol Oncol       Date:  2017-03-18       Impact factor: 5.482

4.  Nonsurgical management of cervical cancer: locally advanced, recurrent, and metastatic disease, survivorship, and beyond.

Authors:  Helen J Mackay; Lari Wenzel; Linda Mileshkin
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

5.  Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix.

Authors:  Muneaki Shimada; Shoji Nagao; Keiichi Fujiwara; Nobuhiro Takeshima; Ken Takizawa; Tadahiro Shoji; Toru Sugiyama; Satoshi Yamaguchi; Ryuichiro Nishimura; Junzo Kigawa
Journal:  Int J Clin Oncol       Date:  2016-07-05       Impact factor: 3.402

6.  Comparison of the survival outcome of neoadjuvant therapy followed by radical surgery with that of concomitant chemoradiotherapy in patients with stage IB2-IIIB cervical adenocarcinoma.

Authors:  Tian Tian; Xudong Gao; Yunhe Ju; Xiang Ding; Yiqin Ai
Journal:  Arch Gynecol Obstet       Date:  2020-10-03       Impact factor: 2.344

7.  A comparison of the prognosis between adenocarcinoma and squamous cell carcinoma in stage IB-IIA cervical cancer.

Authors:  Xiuzhen Xie; Kun Song; Baoxia Cui; Jie Jiang; Xingsheng Yang; Beihua Kong
Journal:  Int J Clin Oncol       Date:  2018-01-03       Impact factor: 3.402

8.  Natural history and outcome of neuroendocrine carcinoma of the cervix.

Authors:  Benjamin Margolis; Ana I Tergas; Ling Chen; June Y Hou; William M Burke; Jim C Hu; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright
Journal:  Gynecol Oncol       Date:  2016-02-09       Impact factor: 5.482

Review 9.  Adenocarcinoma of the cervix: should we treat it differently?

Authors:  Ned L Williams; Theresa L Werner; Elke A Jarboe; David K Gaffney
Journal:  Curr Oncol Rep       Date:  2015-04       Impact factor: 5.075

10.  Pattern classification of endocervical adenocarcinoma: reproducibility and review of criteria.

Authors:  Joanne K L Rutgers; Andres A Roma; Kay J Park; Richard J Zaino; Abbey Johnson; Isabel Alvarado; Dean Daya; Golnar Rasty; Teri A Longacre; Brigitte M Ronnett; Elvio G Silva
Journal:  Mod Pathol       Date:  2016-06-03       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.